Clinical Trial

Disease: B-cell Non-Hodgkin Lymphoma, NHL, (NCT04637763)

Disease info:

B cell lymphoma refers to types of non-Hodgkin lymphoma that are characterised by abnormalities of the "B cells" (a type of white blood cell that makes antibodies to help fight infection). B cell lymphoma may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in a type of white blood cells called lymphocytes, which are part of the body’s immune system. NHL is a term that's used for many different types of lymphoma that all share some of the same characteristics. NHL usually starts in lymph nodes or other lymph tissue, but it can sometimes affect the skin. 

Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. About 77,240 people (42,380 males and 34,860 females) will be diagnosed with NHL. This includes both adults and children.
Official title:
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)


Name: Socorro Portella, MD

Phone: 973 866 7567



United States, Arizona

HonorHealth, Scottsdale, Arizona, United States, 85258


United States, California

University of California San Diego Moores Cancer Center, La Jolla, California, United States, 92073

Chao Family Comprehensive Cancer Center/University of California Irvine, Orange, California, United States, 92868


United States, Iowa

Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States, 52242


United States, New Jersey

Atlantic Health System, Morristown, New Jersey, United States, 07960


United States, Ohio

Oncology Hematology Care, Cincinnati, Ohio, United States, 45242

Ohio State University James Cancer Hospital, Columbus, Ohio, United States, 43210


United States, Texas

Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States, 75246

MD Anderson Cancer Center, Houston, Texas, United States, 77030-4009


United States, Utah

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States, 84112

Study start:
May. 26, 2021
72 participants
Gene editing method:
Cas9 chRDNA (CRISPR hybrid RNA-DNA)
Type of edit:
Gene knock-out, gene knock-in
TRAC knockout CD19-specific CAR PD-1 knockout
Delivery method:
Adeno-associated virus (AAV) - Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting


CB-010 is manufactured from healthy donor T cells using Caribou’s next-generation CRISPR genome-editing technology. Through genome editing, PD-1 is deleted from the CAR-T cells, which in pre-clinical studies promoted an increase in the durability of antitumour activity. Genome editing is used to remove the endogenous T cell receptor in order to prevent graft-versus-host disease and to site-specifically insert the CAR into the CAR-T genome.

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.


  • Genetic: CB-010

    CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.

  • Drug: Cyclophosphamide

    Chemotherapy for lymphodepletion

  • Drug: Fludarabine

    Chemotherapy for lymphodepletion

Last updated: Jul. 31, 2023
Search CRISPR Medicine